These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 15791165

  • 1. Anti-tumor necrosis factor alpha antibody in the treatment of Behçet's disease.
    Nakamura S, Ohno S.
    Int Ophthalmol Clin; 2005; 45(2):179-89. PubMed ID: 15791165
    [No Abstract] [Full Text] [Related]

  • 2. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case.
    Kram MT, May LD, Goodman S, Molinas S.
    Dis Colon Rectum; 2003 Jan; 46(1):118-21. PubMed ID: 12544532
    [Abstract] [Full Text] [Related]

  • 3. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N, Mizoshita T, Sugiyama T, Togawa S, Miyaki T, Suzuki T, Tanida S, Kataoka H, Sasaki M.
    Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
    [Abstract] [Full Text] [Related]

  • 4. Intra-articular anti-tumor necrosis factor alpha antibody in recalcitrant arthritis of Behçet's disease.
    Andonopoulos AP, Meimaris N, Daoussis D, Bounas A, Yiannopoulos G.
    Clin Exp Rheumatol; 2003 Jul; 21(4 Suppl 30):S57-8. PubMed ID: 14727465
    [No Abstract] [Full Text] [Related]

  • 5. Infliximab in refractory uveitis due to Behçet's disease.
    Wechsler B, Sablé-Fourtassou R, Bodaghi B, Huong DL, Cassoux N, Badelon I, Fain O, LeHoang P, Piette JC.
    Clin Exp Rheumatol; 2004 Jul; 22(4 Suppl 34):S14-6. PubMed ID: 15515776
    [Abstract] [Full Text] [Related]

  • 6. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
    Park J, Cheon JH.
    Gut Liver; 2018 Nov 15; 12(6):623-632. PubMed ID: 29788675
    [Abstract] [Full Text] [Related]

  • 7. Long-term infliximab treatment for Behçet's disease.
    Takamoto M, Kaburaki T, Numaga J, Fujino Y, Kawashima H.
    Jpn J Ophthalmol; 2007 Nov 15; 51(3):239-40. PubMed ID: 17554493
    [No Abstract] [Full Text] [Related]

  • 8. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
    Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P.
    Jpn J Ophthalmol; 2007 Nov 15; 51(3):191-6. PubMed ID: 17554481
    [Abstract] [Full Text] [Related]

  • 9. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab.
    Iwata D, Namba K, Mizuuchi K, Kitaichi N, Kase S, Takemoto Y, Ohno S, Ishida S.
    Graefes Arch Clin Exp Ophthalmol; 2012 Jul 15; 250(7):1081-7. PubMed ID: 22234352
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome.
    Licata G, Pinto A, Tuttolomondo A, Banco A, Ciccia F, Ferrante A, Triolo G.
    Ann Rheum Dis; 2003 Mar 15; 62(3):280-1. PubMed ID: 12594127
    [No Abstract] [Full Text] [Related]

  • 11. Effect of infliximab on refractory uveitis in Behcet's disease.
    Sayarlioglu M, Cinal A, Topcu N, Demirok A.
    Ann Pharmacother; 2004 May 15; 38(5):901-2. PubMed ID: 15010522
    [No Abstract] [Full Text] [Related]

  • 12. Antitumor necrosis factor monoclonal antibody therapy in a woman with severe Adamantiades-Behçet's disease.
    Behrens F, Zollner T, Moeller B, Kaltwasser JP, Kaufmann R, Ochsendorf FR.
    Adv Exp Med Biol; 2003 May 15; 528():561-2. PubMed ID: 12918764
    [No Abstract] [Full Text] [Related]

  • 13. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
    Morris DS, Gavin MP, Sturrock RD.
    Adv Exp Med Biol; 2003 May 15; 528():557-9. PubMed ID: 12918763
    [No Abstract] [Full Text] [Related]

  • 14. Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.
    Fujikawa K, Aratake K, Kawakami A, Aramaki T, Iwanaga N, Izumi Y, Arima K, Kamachi M, Tamai M, Huang M, Nakamura H, Nishiura Y, Origuchi T, Ida H, Eguchi K.
    Ann Rheum Dis; 2007 Jan 15; 66(1):136-7. PubMed ID: 17178762
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
    Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, Tanaka Y.
    Rheumatology (Oxford); 2009 Aug 15; 48(8):1012-3. PubMed ID: 19465589
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
    Tognon S, Graziani G, Marcolongo R.
    Ann N Y Acad Sci; 2007 Sep 15; 1110():474-84. PubMed ID: 17911463
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.